Everest Organics Ltd

Everest Organics Ltd has a debt-to-equity ratio of 1.26, indicating a moderate reliance on debt financing, while its current ratio of 0.94 suggests limited short-term liquidity. The company's operating cash flow of INR 164.2 million is positive, but capital expenditures of INR -130.93 million suggest significant reinvestment in operations. The company's return on equity of 0.13% and return on assets of 0.03% are well below the industry median for pharmaceutical firms, indicating weak capital efficiency and asset utilization.

The company's profitability is underperforming relative to its peers, with a net income of INR 583,000 and an operating income of INR 11.08 million, which is a small fraction of its revenue of INR 526.17 million. Gross profit of INR 197.35 million represents a 37.5% margin, but this is not sufficient to cover operating expenses, which consume nearly 98% of gross profit. The company's financial structure and returns suggest a need for operational improvements to align with industry benchmarks.

Everest Organics Ltd's revenue is not segmented by product or geography in the available data, but the company's total revenue of INR 526.17 million is concentrated in a single business line, which increases exposure to market-specific risks. The lack of geographic diversification and product segmentation makes it difficult to assess the company's resilience to regional or product-specific shocks.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. However, the capital expenditure of INR -130.93 million suggests a focus on maintaining or expanding production capacity. The company's operating cash flow of INR 164.2 million provides some flexibility for reinvestment, but the net income of INR 583,000 indicates limited profitability to support long-term growth.

The risk assessment highlights a medium liquidity risk due to a current ratio of 0.94 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company's financial structure and weak returns suggest a need for careful monitoring of liquidity and capital efficiency.

Recent filings and transcripts do not provide specific details on strategic initiatives or major events affecting Everest Organics Ltd. The company's financial performance and risk profile suggest a focus on stabilizing operations and improving returns.

Free cash flow turned positive at INR 102 million in FY-4, reversing previous deficits and indicating improved operational cash generation.

Cash conversion of 281.65% ranks as best-in-class within the pharmaceutical cohort, demonstrating superior efficiency in generating cash from operations.

Long-term debt decreased significantly to INR 211 million in FY-4 from INR 578 million in FY-1, reducing leverage and financial risk.

Operating income expanded to INR 195 million in FY-4, a substantial increase from INR 27 million in FY-3, showing margin improvement.

The company maintains a low leverage band with a debt-to-equity ratio of 0.37, suggesting a conservative capital structure relative to peers.

Return on equity of 0.13% is significantly below the cohort median of 2.92%, reflecting poor capital efficiency for shareholders.